NIP和CAP方案治疗晚期NSCLC的对比观察

Comparative Study of NIP and CAP Regimens in Advanced Non-Small Cell Lung Cancer

目的：对比观察NIP和CAP方案治疗晚期非小细胞肺癌的疗效、不良反应。方法：晚期非小细胞肺癌80例，以随机、对照的原则分为NIP和CAP方案化疗组，对比观察两者间疗效、缓解期和不良反应的差异。结果：NIP组（32例）有效率43．8％与CAP组（48例）有效率35．4％间无显著性差异（P＞0．05）；但NIP方案的中位缓解期5个月较CAP方案的4个月有所延长，两者间有显著性差异（P＜0．05）；在不良反应方面，二组的主要毒性反应都是骨髓抑制，但NIP方案对骨髓造血组织的影响，特别是对粒细胞系和巨核细胞系较CAP方案为重，另外其周围神经炎和静脉炎的发生率也较高。结论：NIP和CAP方案都是治疗晚期NSCLC的较为有效的化疗方案，但NIP方案的中位缓解期较长，毒性反应均可以耐受，如辅以G－CSF防治重度骨髓抑制，NIP方案有更好的临床应用价值。

Objective To contrast the curative effects and toxicities of NIP and CAP in treatment of non－small cell lung cancer NSCLC． Methods Eighty patients with advanced NSCLC were divided randomly into NIP treatment group and CAP treatment group． The efficacy and toxicity in these two groups were contrasted． Results The effective rates of these two groups showed no marked difference NIP regimen 43．8％ CAP35．4％． But the middle remission time of the NIP group 5 months was longer than that of CAP group 4 months P＜0．05． The major toxicity reaction was bone marrow suppression but the incidence of peripheral neuritis and phlebitis in NIP group was higher than those in CAP group． Conclusion NIP and CAP regimen are all effective for advanced NSCLC but the middle remission period of NIP regimen is longer than that of CAP regimen． The toxicity of these two regimens are tolerable and the bone marrow suppression can be prevented or treated by G－CSF． The NIP regimen has a better clinical value as compared with CAP regimen．